Michael L Blute

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy
    Matthew K Tollefson
    Department of Urology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:422-7. 2007
  2. ncbi request reprint The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus
    Michael L Blute
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    BJU Int 94:33-41. 2004
  3. ncbi request reprint A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma
    Michael L Blute
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 172:465-9. 2004
  4. doi request reprint Outcomes following partial nephrectomy by tumor size
    Paul L Crispen
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 180:1912-7. 2008
  5. ncbi request reprint A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials
    Bradley C Leibovich
    Department of Urology, Mayo Medical School, Rochester, Minnesota, USA
    J Urol 174:1759-63; discussion 1763. 2005
  6. ncbi request reprint Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness
    Shomik Sengupta
    Department of Urology, Mayo Medical School and Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer 104:511-20. 2005
  7. ncbi request reprint Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy
    David S Dimarco
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55901, USA
    Urology 64:462-7. 2004
  8. ncbi request reprint Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement
    Igor Frank
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 101:1803-8. 2004
  9. ncbi request reprint Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 104:53-60. 2005
  10. ncbi request reprint Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma
    R Houston Thompson
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 104:2084-91. 2005

Detail Information

Publications100

  1. ncbi request reprint Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy
    Matthew K Tollefson
    Department of Urology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:422-7. 2007
    ....
  2. ncbi request reprint The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus
    Michael L Blute
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    BJU Int 94:33-41. 2004
    ..To report the surgical management, complications and outcomes over three decades by tumour thrombus level for patients with renal cell carcinoma (RCC) and renal venous extension, as surgery is the most effective treatment...
  3. ncbi request reprint A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma
    Michael L Blute
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 172:465-9. 2004
    ....
  4. doi request reprint Outcomes following partial nephrectomy by tumor size
    Paul L Crispen
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 180:1912-7. 2008
    ..We established long-term survival in patients following partial nephrectomy according to tumor size...
  5. ncbi request reprint A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials
    Bradley C Leibovich
    Department of Urology, Mayo Medical School, Rochester, Minnesota, USA
    J Urol 174:1759-63; discussion 1763. 2005
    ..We developed a clinically useful scoring algorithm to predict cancer specific survival for patients with clear cell metastatic renal cell carcinoma (RCC)...
  6. ncbi request reprint Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness
    Shomik Sengupta
    Department of Urology, Mayo Medical School and Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer 104:511-20. 2005
    ..90; P < 0.001). CONCLUSIONS: Histologic coagulative tumor necrosis is an independent predictor of outcome for clear cell and chromophobe RCC, and it should be routinely reported and used in clinical assessment...
  7. ncbi request reprint Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy
    David S Dimarco
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55901, USA
    Urology 64:462-7. 2004
    ..To determine the pathologic features, including histologic subtype and tumor size, associated with multifocal renal cell carcinoma (RCC) and the impact of multifocality on survival after radical nephrectomy, about which controversy exists...
  8. ncbi request reprint Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement
    Igor Frank
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 101:1803-8. 2004
    ..The objective of this study was to assess the ability of these markers to predict disease-associated outcomes and response to chemotherapy in a cohort of patients with LN-positive TCC...
  9. ncbi request reprint Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 104:53-60. 2005
    ....
  10. ncbi request reprint Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma
    R Houston Thompson
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 104:2084-91. 2005
    ..In the current study, the authors updated their primary RCC results with additional follow-up and investigated the potential role of B7-H1 in metastatic RCC...
  11. ncbi request reprint Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
    R Houston Thompson
    Department of Urology and Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Urol 178:459-63; discussion 463. 2007
    ..It was developed from patients who underwent radical retropubic prostatectomy from 1990 to 1993. We investigated the predictive ability of GPSM in the contemporary era...
  12. doi request reprint Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence
    Stephen A Boorjian
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    Eur Urol 59:893-9. 2011
    ..The natural history of biochemical recurrence (BCR) after radical retropubic prostatectomy (RRP) is variable and does not always translate into systemic progression or prostate cancer (PCa) death...
  13. doi request reprint After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer
    Shomik Sengupta
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    BJU Int 101:170-4. 2008
    ....
  14. ncbi request reprint Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy
    Shomik Sengupta
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 68:94-8. 2006
    ..The aim of this study was to assess the additional value of digital image analysis (DIA) of ploidy and proliferation on needle biopsies, in addition to the known preoperative predictors of +SMs at RRP...
  15. pmc Dynamic prediction of metastases after radical prostatectomy for prostate cancer
    Brant A Inman
    Division of Urology, Duke University Medical Center, Durham, NC, USA
    BJU Int 108:1762-8. 2011
    ..The net result is a dynamic tool that renders clinically relevant predictions that change as the patient's clinical status changes throughout the postoperative course...
  16. ncbi request reprint Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome
    Igor Frank
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 97:2425-31. 2003
    ..However, some patients are cured by radical cystectomy alone. The goal of this study was to identify predictors of survival in this cohort...
  17. ncbi request reprint Obesity and survival after radical prostatectomy: A 10-year prospective cohort study
    Sameer A Siddiqui
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 107:521-9. 2006
    ..Obesity and prostate cancer are among the most common health problems affecting American men today. The authors' goal was to assess the impact of obesity on clinical and pathologic features of prostate cancer and long-term outcomes...
  18. ncbi request reprint The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era
    David S Dimarco
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55901, USA
    J Urol 173:1121-5. 2005
    ..We determined the impact that the number of lymph nodes removed at radical retropubic prostatectomy (RRP) has on cancer progression and cause specific survival in pTXNO cases...
  19. ncbi request reprint High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma
    Alexander S Parker
    Department of Urology, Mayo Clinic College of Medicine, Jacksonville, Florida, USA
    Cancer 107:37-45. 2006
    ..What remained in question was whether survivin expression at the protein level is an independent predictor of disease progression and cancer-specific survival...
  20. pmc Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma
    Paul L Crispen
    Department of Urology, Mayo Clinic, Rochester, Minnesota, USA
    Clin Cancer Res 14:5150-7. 2008
    ..As such, we evaluated the association of B7-H3 expression with clinicopathologic outcomes in patients treated for ccRCC...
  21. doi request reprint Long-term complications of conduit urinary diversion
    Mark S Shimko
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    J Urol 185:562-7. 2011
    ..We evaluated long-term surgical complications and clinical outcomes in a large group of patients treated with conduit urinary diversion...
  22. ncbi request reprint Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort
    Igor Frank
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    J Urol 173:1889-92. 2005
    ..In the current study we evaluated the 2002 primary tumor classification and compared its predictive ability with that of the 1997 classification...
  23. ncbi request reprint The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy
    John F Ward
    Department of Urology, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    J Urol 170:1872-6. 2003
    ....
  24. doi request reprint Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques
    Amy E Krambeck
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN 55905, USA
    BJU Int 103:448-53. 2009
    ..To assess the perioperative complications and early oncological results in a comparative study matching open radical retropubic (RRP) and robot-assisted radical prostatectomy (RARP) groups...
  25. ncbi request reprint Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma
    Amy E Krambeck
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
    Clin Cancer Res 13:1749-56. 2007
    ..Herein, we examine the clinical effect of ccRCC combined expression of both survivin and B7-H1...
  26. ncbi request reprint B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma
    R Houston Thompson
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 66:10-4. 2005
    ..35-9.15; P = 0.010). Tumor-associated B7-H1 expression is significantly associated with poor prognosis among patients with clear-cell RCC. Manipulation of B7-H1 with therapeutic intent remains a realistic and viable therapeutic option...
  27. doi request reprint Renal function after partial nephrectomy: effect of warm ischemia relative to quantity and quality of preserved kidney
    R Houston Thompson
    Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    Urology 79:356-60. 2012
    ..To evaluate the effects of warm ischemia time (WIT) and quantity and quality of kidney preserved on renal functional recovery after partial nephrectomy (PN). The effect of WIT relative to these other parameters has recently been challenged...
  28. ncbi request reprint Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
    R Houston Thompson
    Department of Urology, Mayo Medical School, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Res 66:3381-5. 2006
    ..RCC patients with tumor B7-H1 are at significant risk of rapid cancer progression and accelerated rates of mortality. B7-H1 may function as a key determinant in RCC, abrogating immune responses directed against this immunogenic tumor...
  29. doi request reprint Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates
    Paul L Crispen
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    Eur Urol 59:18-23. 2011
    ..Observational studies suggest a proportion of patients with lymph node metastases will benefit from lymph node dissection (LND) at the time of nephrectomy for clear cell renal cell carcinoma (RCC)...
  30. ncbi request reprint Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001
    Shomik Sengupta
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 106:2630-5. 2006
    ..The objectives of the current study were to examine time trends in the prevalence of Gleason grades of prostate cancer on radical retropubic prostatectomy (RRP) specimens and to assess the resultant impact on prognosis...
  31. ncbi request reprint Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 174:1218-21. 2005
    ..We investigated the prognostic significance of each of these pathological features using a cohort of pT3a patients...
  32. ncbi request reprint Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy
    Michael L Blute
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    J Urol 178:440-5; discussion 444. 2007
    ..We describe the indications, technique, complications and outcomes of vena caval interruption during nephrectomy with tumor thrombectomy...
  33. doi request reprint Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient
    Matthew K Tollefson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 75:1373-7. 2010
    ..To determine whether iatrogenic immunosuppression used after transplantation infers a poor prognosis of renal cell carcinoma (RCC) as natural negative immune regulators have been associated with decreased cancer-specific survival from RCC...
  34. doi request reprint Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer
    Sameer A Siddiqui
    Department of Urology, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA
    BJU Int 107:383-8. 2011
    ..To determine the impact of adjuvant androgen deprivation therapy (ADT) on survival in patients with seminal vesicle invasion (pT3b) at radical prostatectomy...
  35. pmc Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma
    Alexander S Parker
    Department of Urology, Mayo Medical School, Jacksonville, Florida, USA
    Cancer 115:2092-103. 2009
    ..In the current study, they described the creation of a scoring system based on this panel of biomarkers that can be used in tandem with existing clinicopathologic features and algorithms to improve ccRCC outcome prediction...
  36. ncbi request reprint The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma
    Michael L Blute
    Department of Urology, Mayo Clinic, Rochester, Minnesota, USA
    J Urol 169:1276-81. 2003
    ..We also analyzed early surgical complications and long-term renal function in patients who underwent staged surgery and those who underwent a single operation for bilateral synchronous renal cell carcinoma...
  37. ncbi request reprint Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension
    Matthew T Gettman
    Department of Urology, Division of Anatomic Pathology and Section of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 169:1282-6. 2003
    ..We analyzed the Charlson co-morbidity index as a predictor of outcome after surgery...
  38. ncbi request reprint Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome
    Kent G Krejci
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 62:641-6. 2003
    ..To determine the clinicopathologic features associated with outcome in patients with sporadic renal cell carcinoma (RCC) treated with nephron-sparing surgery...
  39. ncbi request reprint A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma
    Igor Frank
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    J Urol 170:2225-32. 2003
    ..We designed scoring algorithms for postoperative surveillance based on multivariately significant predictors of site specific disease recurrence...
  40. pmc Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL
    Brant A Inman
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 113:1544-51. 2008
    ..The authors evaluated the long-term outcomes of men with prostate cancer and very high (> or =50 ng/mL) preoperative serum prostate-specific antigen (PSA) values that were treated with radical prostatectomy...
  41. ncbi request reprint Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era
    Stephen A Boorjian
    Department of Urology and Division of Biostatistics, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 178:864-70; discussion 870-1. 2007
    ..We examined the impact of lymph node metastases on the outcome of patients following radical prostatectomy and investigated prognostic factors that affect survival...
  42. doi request reprint Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study
    Sameer A Siddiqui
    Department of Urology, Mayo Clinic, Rochester, Minnesota, USA
    J Urol 179:1830-7; discussion 1837. 2008
    ..We assessed the impact of the timing of androgen deprivation on disease progression after radical prostatectomy for patients with localized prostate cancer...
  43. doi request reprint Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper urinary tract
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN 55905, USA
    BJU Int 102:1107-10. 2008
    ..To report our experience using ureteroscopic or percutaneous management of upper urinary tract (UUT) transitional cell carcinoma (TCC) in patients with no history of bladder TCC...
  44. doi request reprint Treatment of patients with small renal masses: a survey of the American Urological Association
    Rodney H Breau
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55901, USA
    J Urol 185:407-13. 2011
    ..We surveyed American Urological Association members to determine factors that influence the treatment of patients with small renal masses...
  45. pmc B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival
    Amy E Krambeck
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
    Proc Natl Acad Sci U S A 103:10391-6. 2006
    ..Last, we demonstrate that patients with RCC tumors expressing both B7-H4 and B7-H1 are at an even greater risk of death from RCC...
  46. doi request reprint Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma
    Eric C Umbreit
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota55905, USA
    Cancer 116:3399-407. 2010
    ..A scoring algorithm of site-specific disease recurrence after cystectomy for urothelial carcinoma was designed...
  47. pmc Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer
    Stephen A Boorjian
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    Cancer 117:2883-91. 2011
    ..The long-term survival of patients with high-risk prostate cancer was compared after radical prostatectomy (RRP) and after external beam radiation therapy (EBRT) with or without adjuvant androgen-deprivation therapy (ADT)...
  48. ncbi request reprint Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion
    Robert Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 31:1089-93. 2007
    ..Appropriate assessment of nephrectomy specimens should include proper sampling of the renal sinus even for seemingly localized tumors...
  49. ncbi request reprint Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival
    Shomik Sengupta
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 175:1684-90; discussion 1690. 2006
    ..We assessed the natural history of detectable PSA in such patients with particular emphasis on the prognostic usefulness of PSADT...
  50. ncbi request reprint The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma
    Shomik Sengupta
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 106:304-12. 2006
    ..Hence, the current study was conducted to expand on prior observations pertaining to the ESR as a prognostic indicator in patients with RCC...
  51. ncbi request reprint pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival
    John C Cheville
    Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 94:2180-4. 2002
    ....
  52. ncbi request reprint Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy
    Shomik Sengupta
    Department of Urology and Division of Biostatistics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Urol 174:2191-6. 2005
    ..We assessed preoperative PSA doubling time (PSADT) and PSA velocity (PSAV) as predictors of outcome following radical retropubic prostatectomy (RRP)...
  53. ncbi request reprint Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival
    W Scott Webster
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 107:46-53. 2006
    ..The objective of the current study was to evaluate associations between mononuclear cell infiltration in routinely prepared paraffin-embedded specimens with survival in patients with clear-cell RCC...
  54. ncbi request reprint Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma
    Sameer A Siddiqui
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 13:2075-81. 2007
    ..We tested for the presence of putative Tregs within renal cell carcinoma (RCC) tumors...
  55. doi request reprint Metastatic potential of a renal mass according to original tumour size at presentation
    Eric C Umbreit
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    BJU Int 109:190-4; discussion 194. 2012
    ..To determine the metastatic potential of renal masses based on original tumour size...
  56. ncbi request reprint Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers
    Stephen A Boorjian
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    BJU Int 101:299-304. 2008
    ..To investigate whether the clinical and pathological outcomes after radical retropubic prostatectomy (RRP) have changed since the advent of prostate-specific antigen (PSA) testing for patients with Gleason 8-10 cancers...
  57. ncbi request reprint Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 173:918-21. 2005
    ..In the current study we evaluated the association of direct ipsilateral adrenal invasion with outcome to determine if reclassification of these tumors as pT4 would improve the accuracy of the current tumor classification...
  58. ncbi request reprint An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score
    Igor Frank
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    J Urol 168:2395-400. 2002
    ....
  59. ncbi request reprint Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer
    Julie M Cunningham
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 16:969-78. 2007
    ..Given that the point estimates for the odds ratio for each of these polymorphisms are <2.0, much larger sample sizes will be required for confirmation...
  60. ncbi request reprint Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma
    Amy E Krambeck
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 177:1721-6. 2007
    ..We evaluate the role of endoscopic management of upper tract urothelial carcinoma in patients with a history of primary bladder urothelial carcinoma...
  61. ncbi request reprint Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness
    Farhad Kosari
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 11:5128-39. 2005
    ..The objective of this study was to use gene expression profiling to identify novel biomarkers that are predictive of aggressive behavior in clear cell renal cell carcinoma (CCRCC)...
  62. ncbi request reprint Renal cell carcinoma: vena caval involvement
    Stephen A Boorjian
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    BJU Int 99:1239-44. 2007
  63. ncbi request reprint PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
    R Houston Thompson
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
    Clin Cancer Res 13:1757-61. 2007
    ..Levels of immune cells expressing PD-1 (PD-1(+)) in clinical RCC tumors have not been evaluated. Thus, we tested whether immune cell PD-1 expression is observed within aggressive RCC tumors...
  64. ncbi request reprint Imperative indications for conservative management of upper tract transitional cell carcinoma
    Amy E Krambeck
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 178:792-6; discussion 796-7. 2007
    ..We report our experience with patients with imperative indications for endoscopic treatment for upper tract transitional cell carcinoma...
  65. pmc Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases
    Grant Chavin
    Department of Urology, Mayo Clinic, Rochester, Minnesota, USA
    Clin Cancer Res 15:2174-80. 2009
    ..Prostate cancer cells uniformly express the immune cell inhibitory B7-H3 ligand. Enhanced B7-H3 expression correlates with increased disease progression and cancer-specific death after radical prostatectomy (RP)...
  66. ncbi request reprint Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials
    Bradley C Leibovich
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 97:1663-71. 2003
    ....
  67. pmc Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma
    James S Magera
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 71:278-82. 2008
    ..To determine whether preoperative laboratory values are independently associated with death from clinically confined clear cell renal cell carcinoma (RCC) after radical nephrectomy...
  68. ncbi request reprint Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma
    Alexander S Parker
    Department of Urology, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, USA
    Urology 68:741-6. 2006
    ..We used data from a large cohort of patients treated surgically for clear cell RCC to evaluate the association of obesity with the pathologic features of tumor aggressiveness and cancer-specific outcomes...
  69. ncbi request reprint Reassessing the diagnostic yield of saturation biopsy of the prostate
    Richard A Ashley
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    Eur Urol 53:976-81. 2008
    ..This study was performed to determine whether saturation biopsy (>or= 24 cores) detects more prostate cancer than a standard 12-18 core office biopsy technique...
  70. doi request reprint Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol
    Sameer A Siddiqui
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    BJU Int 104:778-85. 2009
    ....
  71. ncbi request reprint Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery
    Reza Ghavamian
    Department of Laboratory Medicine, Health Sciences Research and Urology, Mayo Clinic, Rochester, Minnesota, USA
    J Urol 168:454-9. 2002
    ..We evaluated surgical techniques, pathological features and extended outcomes in patients with renal cell carcinoma in a solitary kidney treated with surgical excision...
  72. ncbi request reprint Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy
    Weber K Lau
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 59:532-7. 2002
    ..CONCLUSIONS: RCC subtype is a strong independent prognostic variable for patients with pT1 RCC treated with radical nephrectomy. For clear cell RCC, Fuhrman grade and tumor size are independently associated with CSS and MFS...
  73. ncbi request reprint Surgical treatment of stage pT3b renal cell carcinoma in solitary kidneys: a case series
    Shomik Sengupta
    Urology Department, Mayo Clinic, Rochester, MN, USA
    BJU Int 96:54-7. 2005
    ..To describe the surgical management of patients with renal cell carcinoma (RCC) in a solitary kidney (managed preferentially by nephron-sparing surgery, NSS, to avoid dialysis) and extending into the renal vein or inferior vena cava (T3b)...
  74. doi request reprint Lymph node dissection in the management of renal cell carcinoma
    Bradley C Leibovich
    Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Urol Clin North Am 35:673-8; viii. 2008
    ..This article examines the rationale for lymphadenectomy in the management of renal cell carcinoma and reviews the limited literature on the subject...
  75. doi request reprint How long is too long? The effect of the duration of anaesthesia on the incidence of non-urological complications after surgery
    Jonathan C Routh
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    BJU Int 102:301-4. 2008
    ....
  76. ncbi request reprint Minimally invasive radical prostatectomy
    Mitchell R Humphreys
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:1169-80. 2004
    ....
  77. ncbi request reprint Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age
    Susan D Sweat
    Department of Urology and Section of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Urol 168:525-9. 2002
    ....
  78. ncbi request reprint The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma
    John F Ward
    Department of Urology, and Section of Biostatistics, Mayo Clinic, Rochester, Minnesota, USA
    J Urol 168:56-60. 2002
    ..We evaluated cancer specific survival differences in patients with clear cell renal cell carcinoma and a lymph node stage of pNx, pN0 or pN1/pN2...
  79. ncbi request reprint Update on pathologic staging of renal cell carcinoma
    Matthew T Gettman
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 60:209-17. 2002
  80. doi request reprint Radical prostatectomy for prostate cancer after ileal pouch-anal anastomosis offers oncologic control and sustains quality of life
    Eric C Umbreit
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN, USA
    J Am Coll Surg 210:232-9. 2010
    ..We evaluated the feasibility and oncologic durability of performing prostate biopsy and open radical retropubic prostatectomy (RRP) in patients who have previously undergone proctocolectomy and ileal pouch-anal anastomosis (PC-IPAA)...
  81. ncbi request reprint Tissue ablation technologies for localized prostate cancer
    Michael D Gillett
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:1547-55. 2004
    ..Although still in the beginning stages, these newer forms of treatment offer exciting potential for first-line and second-line treatment of this common urologic malignancy...
  82. doi request reprint Radical retropubic prostatectomy in immunosuppressed transplant recipients
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55902, USA
    J Urol 179:1349-52; discussion 1352-3. 2008
    ..We reviewed our experience with radical retropubic prostatectomy in patients with solid organ transplants...
  83. doi request reprint Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma
    Bradley C Leibovich
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 183:1309-15. 2010
    ..We examined the significance of histological subtype on progression to distant metastasis and cancer specific death after nephrectomy...
  84. ncbi request reprint Can the kidney function as a lung? Systemic oxygenation and renal preservation during retrograde perfusion of the ischaemic kidney in rabbits
    Mitchell R Humphreys
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    BJU Int 98:674-9. 2006
    ....
  85. ncbi request reprint Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy
    Brant A Inman
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Urology 68:604-8. 2006
    ..Controversy exists as to which form of therapy is most effective for high-grade prostate cancer (PCa)...
  86. ncbi request reprint Radical retropubic prostatectomy and blood transfusion
    Gregory A Nuttall
    Department of Anesthesiology, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:1301-5. 2002
    ....
  87. ncbi request reprint Wegener's granulomatosis presenting as renal mass: a case for nephron-sparing surgery
    Amy E Krambeck
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55901, USA
    Urology 65:798. 2005
    ..The renal mass and concerns about possible malignancy obscured the diagnosis of WG. This case illustrates that WG should be considered in the differential diagnosis of solid renal masses...
  88. doi request reprint Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 71:713-7. 2008
    ..We report our experience using ureteroscopic or percutaneous management of upper tract transitional cell carcinoma (TCC) in elective situations...
  89. ncbi request reprint Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma
    John C Cheville
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Surg Pathol 27:612-24. 2003
    ..Our results demonstrate that there are significant differences in outcome and associations with outcome for the different histologic subtypes of RCC, highlighting the need for accurate subtyping...
  90. ncbi request reprint The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer
    Charles Y F Young
    Department of Urology, Mayo Medical Graduate School and Mayo Graduate School, Mayo Clinic Foundation, Rochester, Minnesota, 55905, USA
    Curr Med Chem 11:909-23. 2004
    ..We further discuss the potential implication of these dietary chemicals on prevention of development and progression of prostate cancer...
  91. ncbi request reprint Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy
    Bradley C Leibovich
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 171:1066-70. 2004
    ..We compared outcomes between patients treated with nephron sparing surgery (NSS) without imperative indications for renal preservation and radical nephrectomy (RN) for 4 to 7 cm renal cell carcinoma (RCC)...
  92. ncbi request reprint The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma
    Amy E Krambeck
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 176:1990-5; discussion 1995. 2006
    ..Studies have demonstrated increased time to progression when cytoreductive nephrectomy is performed for metastatic renal cell carcinoma. We evaluated the role of nephron sparing surgery in these patients...
  93. ncbi request reprint Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses
    Michael D Gillett
    Division of Urology, Southern Illinois University, Springfield, Illinois, USA
    J Urol 173:1893-6. 2005
    ..These factors likely contributed to improved cancer specific survival for younger patients...
  94. ncbi request reprint Chemoprevention of prostate cancer
    John F Ward
    Mayo Clinic, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 3:203-14. 2003
    ..Much of the current support for these agents is epidemiologically based, but new prospective studies are now underway which may support their use in conventional medical practice...
  95. ncbi request reprint Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome
    John F Ward
    Division of Urology, Naval Medical Center, Portsmouth, VA, USA
    BJU Int 95:751-6. 2005
    ....
  96. ncbi request reprint Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes
    John F Ward
    Division of Urology, Department of Surgery, Naval Medical Center, Portsmouth, Virginia, USA
    J Urol 173:1156-60. 2005
    ..We present a 30-year experience with performing salvage surgery in patients with persistent prostate cancer (PCA) after definitive radiotherapy...
  97. ncbi request reprint The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy
    John F Ward
    Division of Urology, Department of Surgery, Naval Medical Center, Portsmouth, Virginia, USA
    J Urol 172:1328-32. 2004
    ..We examined whether neurovascular bundle preservation during RP is a risk factor for positive SMs and progression-free survival after adjusting for disease severity...
  98. ncbi request reprint Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival
    John C Cheville
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 95:1028-36. 2002
    ..The objective of this study was to examine the clinical and pathologic features of metastatic prostate carcinoma to bone in a large cohort of men, and the associations of these features with outcome...
  99. doi request reprint Re: Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. V. Margulis, P. Tamboli, S. F. Matin, M. Meisner, D. A. Swanson and C. G. Wood. J Urol 2007; 178: 1878-1882
    R Houston Thompson
    J Urol 180:409; author reply 409-10. 2008